NCT06342960 - KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

October 31, 2028

Study Completion Date

January 31, 2029

Conditions

Lupus NephritisLupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IV

Interventions

BIOLOGICAL

KYV-101 anti-CD19 CAR-T cell therapy

DRUG

Standard lymphodepletion regimen

Trial Locations (6)

RECRUITING

Charite- Universitätsklinikum Berlin, Berlin

RECRUITING

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

RECRUITING

Universitätsklinikum Düsseldorf, Düsseldorf

RECRUITING

Universitätsklinikum Erlangen, Erlangen

RECRUITING

Fraunhofer-Institut für Translationale Medizin und Pharmakologie ITMP, Frankfurt

RECRUITING

Universitätsklinikum Hamburg-Eppendorf, Hamburg